Evaluating diverse technologies for detecting and validating senescent cells in vivo
Project Number1UG3CA268105-01
Contact PI/Project LeaderMELOV, SIMON
Awardee OrganizationBUCK INSTITUTE FOR RESEARCH ON AGING
Description
Abstract Text
PROJECT SUMMARY
Single cell profiling has recently exploded into mainstream biology. Single cell profiling has been employed
in myriad applications in biology, including multiple diseases, embryonic development, comparative
evolutionary studies and aging. Most recently, single cell profiling has informed the phenomena of cellular
senescence. This proposal has two phases, UG3 (model systems), and UH3 (human validation).
Cellular senescence is a multi-faceted cell fate that arrests cell proliferation, essentially irreversibly, and
activates the production and secretion of pro-inflammatory cytokines, chemokines, growth factors, proteases
and lipids, termed the Senescence Associated Secretory Phenotype (SASP). The SASP can influence tissue
microenvironments, and thus senescent cells can strongly affect tissue function and likely the systemic milieu.
Senescent cells increase with age and can drive a growing list of age-related pathologies, ranging from
neurodegeneration to cancer, in part through the SASP.
There is increasing evidence that there are no universal markers for senescent cells. Instead, senescent
cells, while sharing certain characteristics and biomarkers, are remarkably heterogeneous, varying in
characteristics with genotype, cell and tissue type, senescence inducer, tissue (and cell culture)
microenvironment, and chronology (time after initial senescence induction).
While some of the more commonly employed senescence markers have utility in superficially identifying
senescent cells de novo, the onus remains on the investigator to demonstrate why a cell should be considered
senescent, rather than relying on historical markers such as p16INK4a or p21Cip1. Thus, new technologies
designed to identify novel senescent cells and phenotypes are necessary that will require validation
both in culture and in tissue.
The ultimate goal of this proposal is to develop new technologies to map senescent signatures back to
intact human tissue. This goal will enable us to identify and spatially characterize senescent cells in each
tissue, uncovering unique markers depending on tissue and cell type.
Pilot 1: Identify senescent cells in the mouse vasculature, and determine if they can be detected by
ultrasound, and verified in human tissue; Pilot 2: Develop a microphysiologic ex vivo tissue-on-a-chip to model
ovarian senescence, and human tissue-tissue interactions via the SASP.
These two pilots will use a combination of cell surface markers identified in our initial profiling, and Digital
Spatial Profiling (DSP, Nanostring) or Visium (10x) to localize senescent signatures to morphological structures
and cells in tissue sections. Our proposal will develop validated markers of senescence in multiple tissues and
cell types not previously characterized to deploy these technologies to the broader community.
Public Health Relevance Statement
PROJECT NARRATIVE
We will determine the feasibility of detecting senescent cells in two distinct tissues – the ovary and the
vasculature using novel technologies. We will evaluate molecular markers of cellular senescence in single cells
and biofluids using a combination of gene and protein expression, and secreted proteins. If successful in our
initial pilots, we will validate our approaches in human biopsies, demonstrating broad clinical utility of these
emerging technologies.
No Sub Projects information available for 1UG3CA268105-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1UG3CA268105-01
Patents
No Patents information available for 1UG3CA268105-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1UG3CA268105-01
Clinical Studies
No Clinical Studies information available for 1UG3CA268105-01
News and More
Related News Releases
No news release information available for 1UG3CA268105-01
History
No Historical information available for 1UG3CA268105-01
Similar Projects
No Similar Projects information available for 1UG3CA268105-01